Arcus Biosciences, Inc. (NYSE: RCUS) is a Healthcare company (Biotechnology) with a market capitalization of $2.4B. The Maz Rating grades it against the other companies in its sector.
Arcus Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.86, Arcus Biosciences, Inc. trades at 24.3x sales and 6.0x book value. Over the last twelve months it generated about $100M of revenue and a net loss of $526M. It runs a gross margin of 95.0%, an operating margin of -475.0% and a net margin of -445.0%. It shows return on equity of -90.0%, return on invested capital of -75.0% and a free cash flow yield of -19.2%. On the balance sheet: a debt-to-equity ratio of 0.32 and a current ratio of 3.34. Over the past 52 weeks the share price ranged from $16.76 to $31.74, with a beta of 0.81.
Arcus Biosciences, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 15 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Arcus Biosciences, Inc. (RCUS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.36% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.9% / 30% · Interest income / Revenue 66.7% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 3.36% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 20.8% / 33% · Receivables / Mkt Cap (36m) 0.59% / 49% · Interest income / Revenue 66.7% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 3.36% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 20.8% / 33.33% · Receivables / Mkt Cap (24m) 0.59% / 33.33% · Interest income / Revenue 66.7% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 10.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 80.8% / 33.33% · Receivables / Avg Assets (4Q) 1.99% / 33.33% · Interest income / Revenue 66.7% / 5% | Fail |
| FTSE | Debt / Total Assets 12.5% / 33.33% · (Cash+ST Inv) / Total Assets 77.0% / 33.33% · (Cash+Recv) / Total Assets 79.2% / 33.33% · Interest income / Revenue 66.7% / 5% | Fail |
No. As of September 2026, Arcus Biosciences, Inc. (RCUS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Arcus Biosciences, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 66.7% of each dividend: Arcus Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.